0 0

Cited 0 times in

Can DAPT be discontinued at one month after PCI in high bleeding risk patients presenting with ACS?

DC Field Value Language
dc.contributor.author홍명기-
dc.date.accessioned2025-07-09T08:36:18Z-
dc.date.available2025-07-09T08:36:18Z-
dc.date.issued2024-05-
dc.identifier.issn1774-024X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/206520-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherSociété Europa édition-
dc.relation.isPartOfEUROINTERVENTION-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAcute Coronary Syndrome* / therapy-
dc.subject.MESHDual Anti-Platelet Therapy / adverse effects-
dc.subject.MESHDual Anti-Platelet Therapy / methods-
dc.subject.MESHHemorrhage* / chemically induced-
dc.subject.MESHHumans-
dc.subject.MESHPercutaneous Coronary Intervention* / adverse effects-
dc.subject.MESHPlatelet Aggregation Inhibitors* / administration & dosage-
dc.subject.MESHPlatelet Aggregation Inhibitors* / adverse effects-
dc.subject.MESHPlatelet Aggregation Inhibitors* / therapeutic use-
dc.subject.MESHRisk Factors-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.titleCan DAPT be discontinued at one month after PCI in high bleeding risk patients presenting with ACS?-
dc.typeArticle-
dc.contributor.collegeOthers-
dc.contributor.departmentGangnam Severance Hospital (강남세브란스병원)-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.contributor.googleauthorYong-Joon Lee-
dc.identifier.doi10.4244/EIJ-E-24-00027-
dc.contributor.localIdA04391-
dc.relation.journalcodeJ00800-
dc.identifier.eissn1969-6213-
dc.identifier.pmid39230274-
dc.contributor.affiliatedAuthor홍명기-
dc.citation.volume20-
dc.citation.number10-
dc.citation.startPagee621-
dc.citation.endPagee622-
dc.identifier.bibliographicCitationEUROINTERVENTION, Vol.20(10) : e621-e622, 2024-05-
Appears in Collections:
7. Others (기타) > Others (기타) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.